Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.

RL, Ferris; R, Haddad; C, Even; M, Tahara; M, Dvorkin; TE, Ciuleanu; PM, Clement; R, Mesia; S, Kutukova; L, Zholudeva; A, Daste; J, Caballero-Daroqui; B, Keam; I, Vynnychenko; C, Lafond; J, Shetty; H, Mann; J, Fan; S, Wildsmith; N, Morsli; J, Fayette; L, Licitra

doi:10.1016/j.annonc.2020.04.001

Public

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.

Shared by NobleBlocks on Apr 12, 2020 • 12:00 AM UTC

Authors:

Ferris RL

Haddad R

Even C

Abstract

<h4>Background</h4>Targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Combining immunotherapies targeting PD-L1 and cytotoxic T-lymphocyte-associ...

Subject

Immunotherapy

Metastatic

Randomized Clinical Trial

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!